In 2021, Neamati group designed a ZFP91 degrader 189 (XD2-149, Fig. 52) based on Napabucasin, which was undergoing multiple clinical trials and was reported to inhibit STAT3, and the degrader 189 (XD2-149) resulted in inhibition of STAT3 signaling in pancreatic cancer cell lines without inducing proteasome-dependent degradation of STAT3.346 Proteomics analysis showed that it could induce the degradation of the E3 ubiquitinprotein ligase ZFP91 with DC50 values of 80 nM in BxPC-3 cells. This evidence concerns the gene STAT3 and familial pancreatic carcinoma.